Educational Symposium
Prevention of CKD-Associated Hyperphosphatemia in 2025: What Are the Risks and Benefits?
November 06, 2025 | 12:45 PM - 01:45 PM
Location: Room TBD2, Hilton Americas-Houston
Session Description
Hyperphosphatemia in patients with CKD who are on kidney replacement therapy is associated with poor patient outcomes and cardiovascular mortality. A cascading combination of dietary modifications and prescription therapies are used, and efforts toward maintaining target serum phosphorous levels are a major activity in dialysis centers worldwide. Nevertheless, results are mixed, and patient burden directed toward maintaining these levels can be high. This symposium critically assesses the evidence used to justify current treatment targets, with a focus on potential cardiovascular benefits and the role of traditional vs. novel treatment modalities.
Support is provided by an educational grant from Ardelyx, Inc.
Learning Objective(s)
- Describe the evidence-based phosphorus treatment goals in CKD
- Identify cardiovascular complications of hyperphosphatemia
- List potential treatment strategies for hyperphosphatemia, including their relative strengths and weaknesses
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
- CKD Non-Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Current Phosphorus Targets in CKD: Evidence and Available Strategies
12:55 PM - 01:15 PM
- Cardiovascular Effects of Hyperphosphatemia: Does Treatment Modality Matter?
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM